{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-004128","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-08-13T21:06:26+00:00","discovered_at":"2026-08-13T21:08:00.145650+00:00","generated_at":"2026-08-13T21:08:17.326692+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silexion restates FY2025 financials for 1-for-10 reverse split; auditor flags going concern","bullets":["FY2025 net loss $11.9M vs $16.5M in 2024; operating loss $11.6M vs $12.6M.","Cash and equivalents $5.99M at Dec 31, 2025, up from $1.19M; total assets $7.2M.","Auditor expresses substantial doubt about ability to continue as going concern due to recurring losses.","1-for-10 reverse split effective May 28, 2026; all share and per-share data retroactively adjusted.","R&D spend rose to $7.1M from $5.8M; G&A fell to $4.5M from $6.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-004128","json":"https://secwatch.observer/filing/0001178913-26-004128.json","markdown":"https://secwatch.observer/filing/0001178913-26-004128.md","text":"https://secwatch.observer/filing/0001178913-26-004128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004128/0001178913-26-004128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004128/zk2635957.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T21:08:17.326692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}